1.The use of daclizumab in liver transplantation patients
Shusen ZHENG ; Anwei LU ; Tingbo LIANG ; Weilin WANG ; Yan SHEN ; Min ZHANG
Chinese Journal of General Surgery 1997;0(04):-
Objective To evaluate the efficacy and safety of daclizumab(zenapax) in liver transplantation patients with renal insufficiency. Methods We reviewed the use of daclizumab in 50 patients with renal insufficiency or at high risk of renal insufficiency during the period of liver transplantation between March 2001 to February 2003. The control group included 62 cases with no renal insufficiency at the same period. Results Renal function was recovered in 36 of 37 patients. The administration of daclizumab caused no vital organ dysfunction. Acute rejection was 6% (3/50) vs. 29 % (18/62) (P=0.826), infection was 56% (28/50) vs. 58% (36/62)(P=0.826). Conclusion Immunoprophylaxis with daclizumab regimen is safe, effective and well tolerated, and does not lead to increased opportunistic infections, and helps in improving renal function, by reducing the dosage and postponing the application of calcineurin inhibitor.
2.Clinical investigation of entecavir combined with adefovir dipivoxil in the treatment of lamivudine -resistant hepatitis B cirrhosis
Jianwei PAN ; Xuehui JIANG ; Ming LI ; Lingfei JIN ; Anwei ZHENG ; Wei YANG
Chinese Journal of Primary Medicine and Pharmacy 2015;(23):3613-3615
Objective To investigate the clinical effect of entecavir combined with adefovir dipivoxil in the treatment of lamivudine -resistant hepatitis B cirrhosis,to provide a reference for clinical treatment.Methods 117 cases of liver cirrhosis with lamivudine resistance were selected,they were divided into the control group and the observation group according to treatment.60 cases in the observation group used entecavir and adefovir combination therapy,57 cases in the control group was given lamivudine combined with adefovir dipivoxil.The HBeAg conversion rate,HBV -DNA negative rate,liver function,liver function Child -pugh score were compared between two groups.Results After treatment for 24 weeks,48 weeks,the HBV -DNA negative conversion rates in the observation group were 75.00%, 95.00%,which were higher than those in the control group,the differences were statistically significant (χ2 =4.251, P =0.024;χ2 =4.535,P =0.018).In the observation group,ALB,ALT,TBiL,PT improved better than the control group,the differences were statistically significant(t =4.229,P =0.025;t =6.214,P =0.008;t =5.514,P =0.014;t =5.233,P =0.017).After treatment,CTP of the observation group was (7.15 ±1.05)points,which was significantly lower than the control group (8.86 ± 1.47)points,the difference was statistically significant (t =5.874,P =0.010).The incidence rate of adverse reactions between the two groups showed no statistically significant difference (P >0.05).Conclusion Entecavir combined with adefovir dipivoxil therapy has good effect for lamivudine -resistant liver cirrhosis,which will help to improve liver function,inhibit HBV replication,it is worthy of clinical application.
3.Orthotopic liver transplantation with no veno-venous bypass.
Shusen ZHENG ; Dongsheng HUANG ; Jian WU ; Weilin WANG ; Yan SHEN ; Min ZHANG ; Qingyun SHEN ; Anwei LU ; Peifen FU ; Xiao XU
Chinese Journal of Surgery 2002;40(5):326-328
OBJECTIVETo assess the feasibility and outcome of orthotopic liver transplantation (OLT) with no veno-venous bypass (VVB) in adult patients.
METHODSBetween 1999 and June 2001, 43 adult patients were subjected to orthotopic liver transplantations with veno-venous bypass (28), or no veno-venous bypass (15).
RESULTSThere was no significant difference in mean serum creatinine on day 3 and gas discharge time in patients with veno-venous bypass or not. With no veno-venous bypass, the average operative time was 5.6 +/- 1.4 h, median amount of blood loss during operation was 4 200 +/- 850 ml, median amount of blood transfused intraoperatively was 4 800 +/- 920 ml, and median intensive care unit stay was 6.3 days. All these were lower or shorter than those of the patients with veno-venous bypass.
CONCLUSIONSOrthotopic liver transplantation with no veno-venous bypass is safe and can be performed in the majority of adult patients. Liver transplantation with no veno-venous bypass is associated with shorter total operating time, lower blood product usage, and shorter intensive care unit stay compared with standard technique of OLT with routine use of VVB.
Adult ; Creatinine ; blood ; Feasibility Studies ; Female ; Hepatic Veins ; surgery ; Humans ; Liver Diseases ; blood ; surgery ; therapy ; Liver Transplantation ; methods ; Male ; Middle Aged ; Outcome Assessment (Health Care) ; Vascular Surgical Procedures
4.Preparation and characterization of magnetic nano-particles with radiofrequency-induced hyperthermia for cancer treatment.
Xiangshan FAN ; Dongsheng ZHANG ; Jie ZHENG ; Ning GU ; Anwei DING ; Xiupeng JIA ; Hongyun QING ; Liqiang JIN ; Meiling WAN ; Qunhui LI
Journal of Biomedical Engineering 2006;23(4):809-813
Mn0.5Zn0.5Fe2O4 nano-particles were prepared by the chemical co-precipitation, their characteristics were observed with transmission electron microscope (TEM), X-ray diffractometer (XRD) and thermal analysis system, and etc. The temperature changes of the nano-particles of Mn0.5Zn0.5Fe2O4 and its magnetic fluid explored in radiofrequency(RF,200 KHz, 4 KW) were measured. The proliferation ratio of L929 cells cultured in soak of Mn0.5Zn0.5Fe2O4 nano-particles were observed. The experiment indicates that the magnetic particles were about 40 nm diameter in average, round, had strong magnetism, and were proved to be consistent with the standard data of chart of XRD. Its magnetic fluid exposed to RF could be heated up to temperature range from 40 degrees C to 51 degrees C due to the amount of the magnetic nano-particles and intensity of the alternating magnetic field. Magnetic nano-particles were found to have no obvious cytotoxicity to L929 cells.
Animals
;
Cell Line
;
Ferrous Compounds
;
Hyperthermia, Induced
;
Magnetics
;
instrumentation
;
therapeutic use
;
Manganese
;
Materials Testing
;
Mice
;
Nanostructures
;
Zinc
5. The association between aflatoxin exposure and primary hepatocellular carcinoma risks: a case-control study in Chongqing
Chuanfen ZHENG ; Hui ZENG ; Jia WANG ; Hui LIN ; Xiaobin FENG ; Ji'an CHEN ; Zhiqun QIU ; Jiaohua LUO ; Anwei XU ; Lingqiao WANG ; Yao TAN ; Shu CHEN ; Peng JIANG ; Weiqun SHU
Chinese Journal of Preventive Medicine 2017;51(6):539-545
Objective:
To investigate the association between aflatoxin exposure and primary hepatocellular carcinoma (PHC) development.
Methods:
From December 2013 to May 2016, we selected 214 patients newly diagnosed with PHC as cases, and 214 patients as controls from three hospitals in Chongqing. Cases were confirmed with PHC diagnosis standard. And cases caused by clear reasons such as drug-induced liver injury, alcoholic liver damage, fatty liver and gallstones etiology, were excluded. Controls were included with no cancer and no digestive system disease, and recruited simultaneously with cases. Cases and controls were frequency-matched (1∶1) by same gender and age (±3 years). Peripheral blood and random urine samples were collected and analyzed for serum HBsAg status by biochemistry analyzer, and serum AFB1-ALB adduct and urinary AFB1-N7-GUA adduct by ELISA. Basic information, living habits and history of disease for patients were obtained by questionnaires. We used wilcoxon rank sum test to compare the median of serum AFB1-ALB adduct and urinary AFB1-N7-GUA adduct in cases and controls. Logistic regression analyses were performed to assess risk factors for PHC, and synergism index (